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introduction of organized screening programme. CONCLU-
SIONS: The introduction of organized cervical screening pro-
gramme resulted in a 4.2% increase in screening rate in the target
age group of women aged 45–64 years. The effect of organized
cervical screening on screening rate (attendance) was very low.
In order to reduce cervical cancer mortality, screening rate (atten-
dance) must be increased.
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OBJECTIVES: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. Women
between the ages 25–65 are invited by a personal letter and a 3
years screening interval has been applied. The aim of this study
is to analyse the three year screening rate (attendance or cover-
age) of the organized programme according to the age-group of
target population. METHODS: The data derive from the ﬁnan-
cial database of the National Health Insurance Fund Adminis-
tration (OEP) of Hungary covering the period of 2000–2002 and
2003–2005. We calculated the three-year screening rate for
2003–2005 according to the age-group of women. Screening is
deﬁned with cytological examination of Papanicolau smear and
includes all smears taken either within or outside of the orga-
nized programme. RESULTS: The three-year screening rate of
women aged 25–64 years increased from 48, 45% in 2000–2002
without organized screening programme to 52, 65% in
2003–2005 following the introduction of organized screening
programme. The three-year screening was the following in
2003–2005 according the age-groups: 25–29 years: 64, 24%;
30–34 years: 66%; 35–39 years: 60, 89%; 40–44 years: 55,
34%; 45–49 years: 50, 44%; 50–54 years: 49, 23%; 55–59
years: 39, 74%; 60–64 years: 31, 80%. CONCLUSIONS: After
the introduction of organized cervical screening programme we
found the highest screening rate in the age-group 30–34 years
followed by a gradually decreasing screening rates in the higher
age-groups. In order to achieve the expected mortality decline
from cervical cancer, the screening rate (attendance) of women
40–64 should be increased.
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OBJECTIVES: In modeling studies, choosing the epidemiologi-
cal data sources to best represent the future clinical situation can
be a complex issue. Here we compare two methods, a cohort
approach and a cross-sectional approach, to determine the
number of cervical cancer cases and mortalities expected to
occur, both with and without HPV-16/18 vaccination in two
countries having diverse risk factors for HPV infection and pro-
gression to cervical cancer. METHODS: Using a previously
developed Monte Carlo Discrete Event model that uses popula-
tion data to estimate the expected age-speciﬁc number of HPV
infections, cervical cancer cases and deaths, we examined the
challenges of using cross-sectional epidemiological data vs. fol-
lowing a cohort of women hypothetically over their lifetime. The
model estimated the cancer cases and mortality avoided in the
presence of vaccination (base-case: 100% vaccine uptake; no
waning of protection; 95.1% lifetime efﬁcacy against HPV
16/18). RESULTS: The number of cervical cancer cases predicted
using the cohort approach were 4584 in Poland and 37,935 in
Mexico, whereas the number of cervical cancer cases predicted
using the cross-sectional approach were 4358 in Poland and
11,059 in Mexico. Following vaccination in each country, the
number of predicted cervical cancer cases averted would differ,
depending on which method was used, between 3201 (cohort)
and 3043 (cross-sectional) in Poland, and between 22,452
(cohort) and 6545 (cross-sectional) in Mexico. CONCLUSION:
In modeling the natural history of HPV infection and cervical
cancer, one must consider whether the number of cervical cancer
cases is expected to remain stable (in line with current popula-
tion epidemiology and risk factors for HPV infection and devel-
opment of cervical cancer) in light of expected changes over time
in risk factors for the disease, including sexual behaviour, pop-
ulation demographics and screening programs. In addition, all
model assumptions and limitations should be clearly stated.
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OBJECTIVE: A Markov model simulating the long term pre-
vention effects against cervical cancer (CC) of an HPV-vaccine
has been calibrated for France. With this model we particularly
assess the difference in impact of a 20 year HPV vaccination
campaign of girls when starting vaccination with a different 
age-cohort. METHODS: The Markov model was built in
Microsoft®Excel software. It replicates the natural history of
HPV infection to CC over lifetime of a particular age-cohort of
girls. The model simulates the effect of adding vaccination to the
current screening program in terms of number of CC cases and
CC deaths avoided. All transition probabilities of the natural
history of HPV-infection to CC and the screening patterns were
obtained from literature review, expert opinion and ofﬁcial
French statistics. Screening coverage is maintained constant over
time in the model (∼60% of the French women screened every 3
years from the age of 25 to 60). Two base-case scenarios (start-
ing vaccination with different age-groups (11 to 13 versus 15 to
17-year-old + a catch up to the age of 25-year-old) were com-
pared with 100% vaccine coverage on 1st year at starting age +
each year thereafter over a period of 20 years. Extensive sensi-
tivity analysis was performed on vaccine coverage, HPV-preva-
lence, vaccine efﬁcacy. RESULTS: With 100% vaccine coverage
the model predicts a 76% reduction in CC cases (122,441 cases
avoided over lifetime) and the same reduction in CC mortality
(39,422 deaths avoided) when starting the vaccination at the age
of 11–13. With a vaccination at the age of 15–17 the reduction
is reduced to 68%. CONCLUSIONS: In both scenarios a sub-
stantial reduction in cancer cases and mortality due to vaccina-
tion will occur while keeping the current screening strategy.
However, early vaccination will lead to a higher public health
impact.
